Abstract:Introduction: Camrelizumab is a novel anti-programed cell death-1 (PD-1) antibody that has been investigated for the treatment of various malignancies. Increasing immune-related adverse events have been reported in clinical practice, with CD4+ T-cell-mediated-reactive cutaneous capillary endothelial proliferation being the most common. Camrelizumab-induced oral lichenoid reaction (OLR) appears to be a rare adverse effect compared with other anti-PD therapies induced OLR, with the main pathogenesis of activated CD8+ T cells mediating autoimmune reactions. Herein, we report a rare case of camrelizumab-induced OLR and a possible pathogenic mechanism of subepithelial CD4+ T-cell infiltration. Case report: A 57-year-old male patient, who was diagnosed with metastatic esophageal squamous cell carcinoma three years prior, presented with a two-month history of oral erosion that developed while under camrelizumab therapy. Diffuse erythematous and erosive lesions surrounded by bilateral white lesions on the buccal mucosa were detected in his physical examination. Hematoxylin and eosin staining of the lesions revealed the presence of basal keratinocyte degeneration and band-like subepithelial T-cell infiltration. The immunostaining for CD4 on T-cell was positive, while CD8 were sporadically positive. Flow cytometry showed a gradual increase in the CD4+ T-cell proportion in the peripheral blood, with the CD8+ T-cell percentage almost unchanged and in the normal range. We obtained a score of 6 based on the Naranjo algorithm, which means a probable adverse drug reaction. Management and outcome: The patient exhibited notable improvement after two weeks of treatment with topical glucocorticoid without regulating his immunotherapy, and remained in stable condition in the follow-up. Discussion: This case may offer new insight to clinicians on the pathogenesis of anti-PD-1-induced OLR. More critically, it may provide some ideas for a more precise anti-PD therapy or corresponding combination therapy for patients becoming resistant to immunotherapy due to exhausted CD4+ T-cell responses in the tumor microenvironment.

THE ACCUSCAN-II VERTICAL SCANNING GERMANIUM WHOLE BODY COUNTER

Oral Reactive Capillary Hemangiomas Induced by SHR-1210 in the Treatment of Non-Small Cell Lung Cancer: a Case Report and Literature Review

Oral lichen planus pemphigoid : a case report of a rare disease treated by topical Tacrolimus mouthwash and Hydroxychloroquine

PD-1 Inhibitor Induced Hypertrophic Lichen Planus: A Case Report

Lichen planus pemphigoides with predominant mucous membrane involvement: a series of 12 patients and a literature review

Susceptibility of rodents to Japanese encephalitis virus.

Pembrolizumab-induced lichen planus: A rare immune-related adverse side effect

Oral Lichenoid lesions induced by programmed cell death protein 1 and cytotoxic T-lymphocyte-associated protein 4 bispecific antibody: a case report

Lichen Planus Pemphigoides: From Lichenoid Inflammation to Autoantibody-Mediated Blistering

Diffuse Lichen Planus-Like Keratoses and Clinical Pseudo-Progression Associated with Avelumab Treatment for Merkel Cell Carcinoma, a Case Report

[Molecular epidemiology characteristics of human enterovirus coxsackievirus A6 in Guangzhou, in 2011].

Lichenoid mucocutaneous reactions associated with sintilimab therapy in a non-small cell lung adenocarcinoma patient: case report and review

Clinical characteristics, treatment and outcome of subacute cutaneous lupus erythematosus induced by PD-1/PD-L1 inhibitors

Camrelizumab-induced oral lichenoid reaction with subepithelial CD4+ T-cell infiltration

Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature

Reply: "erosive Oral Lichen Planus As a Sign of Paraneoplastic Pemphigus".

Mucous membrane pemphigoid and lichenoid reactions after immune checkpoint inhibitors: common pathomechanisms

Isolation of a new naturally occurring halogenated amino acid: monochloromonobromotyrosine.

Case report: Lichenoid eruption under immunotherapy with MK-4830 and pembrolizumab in a breast cancer patient

Paraneoplastic Pemphigus Characterized by Polymorphic Oral Mucosal Manifestations-Report of Two Cases

Assessment of PD-1 and PD-L1 tissue expression levels in lichen planus patients: a case–control study